Executive Summary


Russian MoH and Biocad rethink FAS’ role in determining drug interchangeability

Interaction with regulators gets to a new level

Russian Supreme Court believes that FAS is not entitled to determine drug interchangeability

Pharma businesses do not believe in bans on drug imports from the USA

Patient associations funded by pharma companies not disclosing this fact


Experts: small retailers will inevitably close down

One in five viral hepatitis patients needs urgent treatment

International companies report on payments in favor of Russian health entities

Citizens’ rights to treatment violated in Russian regions on a mass scale

Public Chamber calls for permitting Rx adverts


Two Erkapharm + three ROSTA pharmacy chains to merge

Insurers willing to service direct contracts between manufacturers and pharmacies

EAEU authorities not entitled to reject NDAs drafted to union’s regulations

Advances of palliative care arrangement discussed in Moscow

Russian cancer care system needs common standards


Pharma market players argue about post Pharma-2020 times

FAS not to disclose reference drug price sources

Bacteriophages have clinical potential given antibiotic resistance

Pharma market players and Moscow officials discussed difficulties of state procurement

New market launches underlie pharma companies’ strategies


VED pricing methodology proposed by MoH fixes prices

MoH revises drug list forming rules

Full-scale contract manufacturing may start in Russia on January 1, 2018

Foreign companies support local manufacture

API manufacturer awaits flexible decision-making from government


The immune drug era may replace the antibiotic era

Moscow and Mexico to exchange public health development experience

Nanotechnologies may help in cancer management

Officials and medical manufacturers considered new medical device registration regulations

MoH continues registering prices of generics of originator drugs still under patents

Регистрируясь, вы принимаете условия
Пользовательского соглашения